Bio-Rad Laboratories Inc. (BIO) on Wednesday reported a third-quarter loss of $341.9 million, after reporting a profit in the same period a ...

Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will ...

Bio-Rad Laboratories Inc. reported its earnings for the second quarter of 2025, revealing a modest increase in net sales and a stable financial performance. Despite a challenging market environment, ...

Investing.com - Bio-Rad Labs B (NYSE: BIOb) reported third quarter EPS of $2.26, $0.37 better than the analyst estimate of $1.89.

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the ...

The Model 422 electro-eluter is an electroelution cell for preparative recovery of biomolecules from agarose and acrylamide gels. The eluter combines with the tank and lid of the Mini Trans-Blot® cell ...

The TC20 automated cell counter counts mammalian cells in one simple step using its innovative auto-focus technology and sophisticated cell counting algorithm to produce accurate cell counts in less ...

Gilead Sciences has bolstered its position in the development of next-generation cancer cell therapies with a deal to absorb Tmunity Therapeutics into its Kite unit. Kite has agreed to acquire all the ...